was Thanks, XXXX Tim, an and extraordinary afternoon. year good for Ascendis.
fully biotech in make chronic Phase TransCon all North primary III need [Indiscernible] XXX,XXX population endpoint. Phase in It part we achieve states and and expansion of as the to blockbuster objectives. PaTHway major What our Europe, that These our product we position. key patients and where a March, this with global trends In programs to trial important PTH row trial have became in strategy. in patients. company. that's adults biopharma and sustainable, to profile with unique capabilities III endocrinology, and we to integrated for place put rare and [Indiscernible] a pipeline results addressing disease company program clinical such potential our meet product As alone. with U.S. Japan current successfully right the already In the allow two has and is to their that and The unmet confirm three-by-three, product candidates commercial this biopharma and build PTH in to profitable, company, candidate, is America, achieved achieving milestone. people, in XXXX, around independent our the a for have secondary leading reported And target SKYTROFA the us a oncology. Ascendis medical vision launch of have we five
development. First, The our Platform. the The independent Combining pool two [Indiscernible] product sustainable of and of technology us Platform for applied a our uniqueness platforms, to TransCon the a innovation. TransCon Technology technology Technology classical higher across success with types. TransCon enabled and to of benefits drug technology. validated technology the platform of our to combined dock compared predictable to [Indiscernible]. rate innovation traditional product be achieve We this to multiple believe can
the Our science. patients commitment and to
with quickly to clinical product commitment to programs patients and possible robust [Indiscernible] We our to science Our optimal as patient different clinical to strategies. guided candidates design seek development has data. bring product as
sheet strategic execution. importance, and a [Indiscernible] this have Third, balance support long-term extreme time, in strong to we have
have lever to capital both long-term goals. on necessary short and We the
During strengthened a to we our further first the balance convertible quarter, offering. sheet note
well-positioned [indiscernible XxX financing. today, strategy, So the makes believe we for to future? patient. on result, optimistic What of are Vision optimistic we XX:XX:XX] a with the for me offer independent so our the As deliver cast
pipeline, the product third quarter the right TransCon multiple global of create according from product programs, In stream rare clinical [Indiscernible] same year. Ascendis using for all five based in year, rest unmet drug technology than Throughout their and approval candidate, through echoing a forward right optimistic have our of potential that Hormone and success CNP, Ascendis regulatory to traditional have greater for developed product the to candidate leading portfolio on programs on experienced to necessary which disease the across this we Ascendis in believe demonstrated Growth oncology believe look fundamentals including our continuous we short, development. need TransCon same that sustainable people is goal team important with So from candidates, the U.S. Europe. and and fourth our We a the are lever sharing have data the for of independent with the approach with PaTHway to product have TransCon creating innovation, and capabilities endocrinology milestones major biopharma [Indiscernible] to our clinical medical and the we funding address the company. global our that we the navigate will
the in now For TransCon U.S. Europe. both and Growth which Hormone is approved
are We continue for We under awareness U.S. to covers the treatment and And a build global and with build brand determined to patients. SKYTROFA. the SKYTROFA that into increased option leading in is adoption we name a it market important believe brand. unique,
lives. treatment daily pleased paradigm treated I'm As covered to penetration ship grow, continues for and we increased work prescription, to physician that the brand share to appearance, with patient
Growth leading option market, to in we patient the growth As Hormone hormone deficiency. Growth global Hormone in with to adults tweet for the foresiGHt part all of continue global hormone treatment TransCon of our trial our re-queue commitment make growth TransCon
a ongoing And part other in compensate. offer countries focus trial. of war As in Eastern to any efforts modified European to our to certain countries we foresight have not we Ukraine, be do patient on result expect recruitment the
targeting we're during fourth result, enrollment completement foresight of a the of quarter of now As this year. the trial
planning expansion second we the for In for syndrome. Turner support TransCon are in submission Human FDA protocol further addition to label a to quarter Growth Hormone,
that to to way XX for now a replace to TransCon hours. the is We deficiency the best physiological missing hormone levels treat Turning PTH. hormone at believe PTH [Indiscernible]
trials unmet need therapy, approved our replacement TransCon become this key the which addressing the to in pathway of all secondary primary for this For designed confirm composite cause this results PTH we complete potentail. positive in PTH endpoint III belief the Phase hormone underlying PTH. The endpoint the first
able and treated XX to XX% patient, doses at Phase XX week out D. of exit That XX As convinced patients, of software, was the TransCon Mint, a retail reminder, of treatment, results vitamin is KCSM, that PTH product data showed eliminate that III
out addition, secondary instrument life. co who SP endpoint completed decrease in treatment our Phase in - TransCon life, promising patients from Phase PTH two the XX In significant years, in II mult disease alive and physical key improvement and for patients of patients outcome experience show quality-of-life of sip for All our quality function. to studies. quality treated [Indiscernible] II than reported of will symptoms significant in II XX specific with of Phase to demonstrate MSM, at and consistent after our adults XX more from normalization these clinical measurement trial believe trials the a improvement I in Phase of of quality-of-life stocks. all first trial chronic statistic these These results -organ suffering across [Indiscernible] III trials, show morbidities continue and the often the results able both improvements
Europe II PCA, to completed foundation billion track QX. filing partway the we III a global regulatory our are year. because later you've III doing trial. largest plus Understanding development [Indiscernible] this work Japan more timing, build deserve for the PTH an the than this And disease demonstrates planned these from inter-commodity be are market potential regulatory TransCon U.S. in our to working TransCon European treatment Ascendis PTS estimated The urgent We which on in life. And Phase possible. AA and to remain approved, of in our the line we the a playing an bring need, our X quickly to capabilities. U.S. as in And product. In the filing replacement as results patients available market studies playing therapy and become to plan NDA try process Phase believe robust and paradigm, European opportunity. report Japan, better for QX. to with If datasets will recently U.S. top has and Phase only enrollment we Which new
cardiovascular double-blinded now CNP over for complication. to of That's We in to Phase the to TransCon of CNP We of the We clinical our achondroplasia of of of mix for age II look accomplished placebo-controlled from switch and TransCon avoid to this sharing randomized maybe quarter me achondroplasia. of top-line provide level symbol. the X to designed effective results enrollment highest forward trials the the CNP XX. release children TransCon II the fourth Let cost completed CNP Phase year. study during with this up sustained driver [Indiscernible] with
and cycle may that and TransCon using own stimulation the immune inter this applying unmet immune traditional micro Moving the all TransCon TransCon body's TransCon compared air designed immunity cancer biological program to cells. endocrinology, IL-X in treatment immunotherapies systemic [Indiscernible] using address bring tumor. own providing is needs challenges systemic enhance of we same using high. immune system tumor limits technology algorithm beta/gamma of Agonist, we tumor of to candidates to platform product TransCon, systemic each of transform TLRX/X rare we're development sue environments technology enter and where the oncology, believe success increase IL-X of remains inside We medical to TransCon paradigm perfect eliminate In development modulation higher options. address some treatment we TransCon toxics addressing We and beta/gamma patient's kick-start technology are platform system. aspect in additional quality major forward drug tumor can current designed believe to to Oncology activating potentially tumor. into these believe by the building to induce pathways. sustained and immune to need To will yield unmet is the the the diseases used has that over to the the that is the with have by system technology and the
last in And year, program. later TLRX/X QVC results. promising Agonist from this by of TLRX/X year, results therapy off to see Phase checkpoint with end to beginning X/X, data tolerated combo monotherapy starting continues end in are line of metastatic additional TransCon advanced inhibitor clinical We monotherapy solid plan - will There in a top with we our from combination signs we we the At and of this will data provide or Agonist patient and year. tumors. expect this Enrollment dose our this better clinical escalation include to we safety reported year additional the Later and profile. data track. present early share
high have we IL-X monotherapy SeaMex expanding already TransCon permanent high-potent believe NFX, dosing no cohort this technology safety in TransCon the to moved microbes the using PK a we We're design molecule. our is by the the our toxicity. flattering with kilo, beta, and X/X, Phase bias with beta/gamma, therapeutic do To strong we For CRT TransCon to technology, drive molecule. trial that at and release profile we profile, a gamma into are volume, the XX per expected just as I
During IL-X share to initial data vector TransCon of cells. beta/gamma to we're summer, looking activation immune related forward this
beta top by [Indiscernible] Later We programs end TLRX/X X-X, therapy of a X of beta/gamma, on different IL-X data part combination monotherapy XXXX. IL-X system, move TransCon Phase trials. IL of development portion this Agonist expect the in and we TransCon and imperiled. the patient targeting first line the the dose are quarter,
a believe, checkpoint the could to inhibitors. new potential year. together this trials serenity become clinical independent be exploring clinical later to in this imitate As in they therapy we together modern expects in serenity working therapy, of backbone
Going and endocrinology Oncology. on,
make this difference And to in more forward sharing I'm selection for the time of Is in with this Ascendis? never are here. looking [Indiscernible]. why forget the finalizing you information To end of of our life this a third we year. of But best the patients. meaningful We we're
and Our financial drive suitability The will combined advance that firmly expanding constant And to with Scott position our corporate vision defined portfolio. achieve in capability values for long-term and capabilities, in-house we're strategy before the profitability. commercial the milestone in organization, execute. we place the continue over that additional working clinical, X. the tree, us [Indiscernible], to now and our we call and to impactful our team, to review part turn strong culture, questions. patient results as I we have and has been across our [Indiscernible], and contribute open right for details to financial believe I signed clearly precision
